Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Galleon Pharmaceuticals

Request full access

Neuro-respiratory medicines for treating breathing control conditions

Horsham Township, United StatesFounded 2003Biotech & Life Sciences

About Galleon Pharmaceuticals

Galleon Pharmaceuticals, Inc. was a pharmaceutical company focused on developing medical drugs to treat conditions related to breathing control. The company was founded in 2003 and was headquartered in Horsham, Pennsylvania. Pitchbook lists James Mannion as the founder and former CEO, who was later succeeded by Joseph Oliveto.

The company's main focus was on creating neuro-respiratory medicines for a range of diseases including sleep apnea, weaning from ventilators, respiratory depression induced by anesthesia, and obesity-hypoventilation syndrome. Their product pipeline included GAL-021, an intravenous drug designed to treat or prevent acute respiratory insufficiency in surgical and critical-care patients. This drug showed positive results in a Phase I clinical study by increasing the capacity of air supplied to the lungs. Galleon also had two other products in preclinical development, GAL-160 oral and GAL-160 oral backups, both intended for sleep apnea treatment.

Galleon Pharmaceuticals was a privately held, venture capital-backed company. It raised approximately $69.6 million in funding from investors, including Ben Franklin Technology Partners of Southeastern Pennsylvania, TPG Biotech, Morgenthaler Ventures, and Healthcare Ventures. In May 2006, the company was named the SR One Biotech Company of the Year. According to PitchBook, the company is now out of business as of February 2019.

Source: Dealroom company data

Galleon Pharmaceuticals in the Horsham Township ecosystem

Live from Dealroom

The Galleon Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BioAdvance
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Horsham Township HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Galleon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Galleon Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.